Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

NCT00949949 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
38
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Mayo Clinic

Collaborators